November 17, 2025 (Global) – Siemens Healthineers is considering a potential exit from its diagnostics business by around 2030, as part of a longer-term portfolio strategy, according to comments from the company’s CEO. The move reflects an ongoing evaluation of how best to position the company for sustainable growth and value creation over the next decade. (Reuters)
“We are looking at all strategic options for our portfolio over the mid to long term,” said [Siemens Healthineers CEO Name], noting that any decision regarding the diagnostics unit would be made carefully and with a long-term perspective.
The diagnostics division, which includes laboratory testing and related solutions, remains an important part of Siemens Healthineers’ business today. However, the company is increasingly focused on higher-growth areas such as imaging, advanced therapies, digital health, and AI-driven solutions. A potential divestment would allow Siemens Healthineers to further concentrate resources and investments on these core segments.
Company leadership emphasized that no immediate decision has been made and that the diagnostics unit continues to perform and support healthcare providers globally. Any future separation or sale would depend on market conditions, strategic alignment, and shareholder value considerations.
Key Highlights
- Siemens Healthineers may consider divesting its diagnostics arm by 2030
- Decision would be part of a long-term portfolio optimization strategy
- Company increasingly focused on imaging, advanced therapies, and digital health
- Diagnostics business remains operational and important in the near to mid term
- No final decision taken; options under evaluation
Industry analysts note that such a move could reshape Siemens Healthineers’ business mix, allowing the company to sharpen its strategic focus while responding to evolving market dynamics in the global medtech sector.
